CDX2 and malignant colon neoplasm: Pilati et al.11 confirmed these results in a publication in Annals of Oncology, based on approximately 500 patients with stage II–III colon cancer, and called for final validation in large cohorts assessing CDX2 expression by immunohistochemistry.